RT Journal Article
SR Electronic
T1 The treatment gap for mental disorders in adults enrolled in HIV treatment programs in South Africa: A cohort study using linked electronic health records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20171058
DO 10.1101/2020.08.10.20171058
A1 Ruffieux, Yann
A1 Efthimiou, Orestis
A1 Van den Heuvel, Leigh L.
A1 Joska, John A.
A1 Cornell, Morna
A1 Seedat, Soraya
A1 Mouton, Johannes P.
A1 Prozesky, Hans
A1 Lund, Crick
A1 Maxwell, Nicola
A1 Tlali, Mpho
A1 Orrell, Catherine
A1 Davies, Mary-Ann
A1 Maartens, Gary
A1 Haas, Andreas D.
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.08.10.20171058.abstract
AB Background Mental disorders are common in people living with HIV (PLWH) but often remain untreated. We aimed to explore the gap in access to treatment (treatment gap) for mental disorders in adults followed-up in antiretroviral therapy (ART) programs in South Africa and disparities in access to mental health services.Methods We conducted a cohort study using ART program data and linked pharmacy and hospitalization data to estimate the 12-month prevalence of treatment for mental disorders (pharmacological or inpatient) and to examine factors associated with the rate of treatment for mental disorders among adults, aged 15-49 years, followed-up from January 1, 2012 to December 31, 2017 at one private care, two pubic primary care, and one public tertiary care ART programs in South Africa. We calculated the treatment gap for mental disorders as the discrepancy between the 12-month prevalence of mental disorders in PLWH (aged 15-49 years) in South Africa (estimated based on data from the Global Burden of Disease study) and the 12-month prevalence of treatment for mental disorders in ART programs. We calculated adjusted rate ratios (aRR) for factors associated with the rate of treatment of mental disorders using Poisson regression.Results 182,285 ART patients were followed-up over 405,153 person-years. In 2017, the estimated treatment gap for mental disorders was 40.5% (95% CI 19.5%-52.9%) for patients followed-up in private care, 96.5% (95% CI 95.0%-97.5%) for patients followed-up in public primary care, and 65.0% (95% CI 36.5%-85.1%) for patients followed-up in public tertiary-care ART programs. Rates of treatment with antidepressants, anxiolytics and antipsychotics were 17 (aRR 0.06, 95% CI 0.06-0.07), 50 (aRR 0.02 95% CI 0.01-0.03), and 2.6 (aRR 0.39, 95% CI 0.35-0.43) times lower in public primary-care programs than in the private-sector ART program.Interpretation There is a large treatment gap for mental disorders in PLWH in South Africa and substantial disparities in access to mental health service between patients receiving ART in the public vs. the private sector. In the public sector and especially in public primary care, PLWH with common mental disorders remain largely untreated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the US National Institutes of Health (the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center (grant number U01AI069924), the Swiss National Science Foundation (SNSF) (grant numbers 174281, P2BEP3_178602, 180083) and the the South African Medical Research Council (SAMRC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained routine data from the International epidemiology Databases to Evaluate AIDS Southern Africa collaboration (IeDEA-SA) [23]. All cohorts participating in IeDEA-SA have ethical approval to examine long-term outcomes of patients through linkage to other datasets, and to contribute de-identified data to the IeDEA-SA Data Centres at the Universities of Cape Town and Bern. The Human Research Ethics Committee of the University of Cape Town, South Africa and the Cantonal Ethics Committee, Bern, Switzerland granted ethical permission for analysis of this database and waived the requirement to obtain informed consent.   All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were obtained through the International epidemiology Database to Evaluate AIDS Southern Africa collaboration (IeDEA-SA, https://www.iedea-sa.org/). Data cannot be made available online because of legal and ethical restrictions. To request data, readers may contact IeDEA for consideration by filling out the online form available at https://www.iedea-sa.org/contact-us/ https://www.iedea-sa.org/